US2003003467A1PendingUtilityA1

Methods for diagnosing and treating pediatric neoplasms

40
Priority: Dec 21, 2000Filed: Dec 18, 2001Published: Jan 2, 2003
Est. expiryDec 21, 2020(expired)· nominal 20-yr term from priority
Inventors:Antonio IavaroneAnna Lasorella
G01N 33/5758G01N 33/575C12Q 1/6886G01N 2800/52C12Q 2600/106C12Q 2600/118C12Q 2600/158
40
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides a method for determining whether a subject has a pediatric neoplasm. The present invention further provides a method for assessing the efficacy of therapy to treat a pediatric neoplasm in a subject who has undergone or is undergoing treatment for a pediatric neoplasm. In addition, the present invention provides a method for assessing the prognosis of a subject who has a pediatric neoplasm. Finally, the present invention provides a method for treating a pediatric neoplasm in a subject in need of treatment thereof.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A method for determining whether a subject has a pediatric neoplasm, comprising assaying a diagnostic sample of the subject for Id2 expression, wherein detection of Id2 expression is diagnostic of a pediatric neoplasm.  
     
     
         2 . The method of  claim 1 , wherein the pediatric neoplasm is a neuroblastoma.  
     
     
         3 . The method of  claim 1 , wherein the diagnostic sample is assayed using an agent reactive with Id2.  
     
     
         4 . The method of  claim 3 , wherein the agent is labeled with a detectable marker.  
     
     
         5 . The method of  claim 3 , wherein the agent is an antibody.  
     
     
         6 . The method of  claim 5 , wherein the antibody is labeled with a detectable marker.  
     
     
         7 . The method of  claim 1 , wherein the diagnostic sample is assayed using at least one nucleic acid probe which hybridizes to nucleic acid encoding Id2.  
     
     
         8 . The method of  claim 7 , wherein the nucleic acid probe is DNA or RNA.  
     
     
         9 . The method of  claim 8 , wherein the nucleic acid probe is labeled with a detectable marker.  
     
     
         10 . A method for assessing the efficacy of therapy to treat a pediatric neoplasm in a subject who has undergone or is undergoing treatment for a pediatric neoplasm, comprising assaying a diagnostic sample of the subject for Id2 expression, wherein detection of Id2 expression in the diagnostic sample is indicative of a need to continue therapy to treat the pediatric neoplasm, and an absence of Id2 expression in the diagnostic sample is indicative of successful therapy.  
     
     
         11 . The method of  claim 10 , wherein the pediatric neoplasm is a neuroblastoma.  
     
     
         12 . The method of  claim 10 , wherein the diagnostic sample is assayed using an agent reactive with Id2.  
     
     
         13 . The method of  claim 12 , wherein the agent is labeled with a detectable marker.  
     
     
         14 . The method of  claim 12 , wherein the agent is an antibody.  
     
     
         15 . The method of  claim 14 , wherein the antibody is labeled with a detectable marker.  
     
     
         16 . The method of  claim 10 , wherein the diagnostic sample is assayed using at least one nucleic acid probe which hybridizes to nucleic acid encoding Id2.  
     
     
         17 . The method of  claim 16 , wherein the nucleic acid probe is DNA or RNA.  
     
     
         18 . The method of  claim 17 , wherein the nucleic acid probe is labeled with a detectable marker.  
     
     
         19 . A method for assessing the prognosis of a subject who has a pediatric neoplasm, comprising assaying a diagnostic sample of the subject for Id2 expression, wherein the subject's prognosis improves with a decrease in Id2 expression in the diagnostic sample, the subject's prognosis worsens with an increase in Id2 expression in the diagnostic sample, the subject's prognosis is favorable at low levels of Id2 expression in the diagnostic sample, and the subject's prognosis is unfavorable at high levels of Id2 expression in the diagnostic sample.  
     
     
         20 . The method of  claim 19 , wherein the pediatric neoplasm is a neuroblastoma.  
     
     
         21 . A method for treating a pediatric neoplasm in a subject in need of treatment thereof, comprising inhibiting Id2.  
     
     
         22 . The method of  claim 21 , wherein the pediatric neoplasm is a neuroblastoma.  
     
     
         23 . The method of  claim 21 , wherein Id2 is inhibited by administering to the subject an amount of an Id2 inhibitor effective to treat the pediatric neoplasm in the subject.  
     
     
         24 . The method of  claim 23 , wherein the Id2 inhibitor is an agent reactive with Id2.  
     
     
         25 . The method of  claim 23 , wherein the Id2 inhibitor is an oligonucleotide antisense to Id2.

Join the waitlist — get patent alerts

Track US2003003467A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.